Literature DB >> 9330760

Alkoxy propane prodrugs of foscarnet: effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1 and HCMV.

G D Kini1, J R Beadle, H Xie, K A Aldern, D D Richman, K Y Hostetler.   

Abstract

The identification of more effective and less toxic foscarnet (PFA) analogs for antiviral therapy would be useful. We recently synthesized 1-O-octadecyl-sn-glycero-3-phosphonoformic acid (ODG-PFA) and noted a 93-fold increase in its anti-HCMV activity relative to PFA. In addition, the antiviral activity of ODG-PFA in herpes simplex virus type-1 (HSV-1) and human immunodeficiency virus type-1 (HIV-1) infected cells was increased 40-fold relative to PFA (Hostetler et al., 1996. Antiviral Res. 31, 59). To evaluate structure-activity relationships further, we synthesized alkoxypropyl esters of foscarnet with varying alkyl chain lengths and degrees of saturation. These compounds were tested in vitro for activity and selectivity in comparison with PFA and ODG-PFA in cells infected with HCMV, HSV-1 or HIV-1. Antiviral activity was strongly dependent on chain length with alkyl ethers 14-18 carbon atoms long exhibiting the greatest antiviral activity against HCMV and HSV-1. In HIV-infected HT4-6C cells, optimal activity was observed at 18-22 carbon chain lengths. The antiviral activities of 1-octadecyloxypropane-3-PFA and 1-docosyloxypropane-3-PFA were 135- and 338-fold greater than that of PFA in HT4-6C cells infected with HIV-1. This also represents a 2.6-6-fold improvement in antiviral activity over ODG-PFA, the previously reported analog.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9330760     DOI: 10.1016/s0166-3542(97)00039-9

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  6 in total

1.  Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.

Authors:  J L Hammond; D L Koontz; H Z Bazmi; J R Beadle; S E Hostetler; G D Kini; K A Aldern; D D Richman; K Y Hostetler; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro.

Authors:  William B Wan; James R Beadle; Caroll Hartline; Earl R Kern; Stephanie L Ciesla; Nadejda Valiaeva; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

3.  Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro.

Authors:  Stephanie L Williams-Aziz; Caroll B Hartline; Emma A Harden; Shannon L Daily; Mark N Prichard; Nicole L Kushner; James R Beadle; W Brad Wan; Karl Y Hostetler; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

4.  Acyclic nucleoside bisphosphonates: synthesis and properties of chiral 2-amino-4,6-bis[(phosphonomethoxy)alkoxy]pyrimidines.

Authors:  Petra Doláková; Martin Dracínský; Milena Masojídková; Veronika Solínová; Václav Kasicka; Antonín Holý
Journal:  Eur J Med Chem       Date:  2008-10-02       Impact factor: 6.514

5.  Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo.

Authors:  John D Morrey; Brent E Korba; James R Beadle; David L Wyles; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

6.  Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Peter R Meyer; Suzanne E Matsuura; Dianna Zonarich; Rahul R Chopra; Eric Pendarvis; Holly Z Bazmi; John W Mellors; Walter A Scott
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.